A personalized neoantigen vaccine + Montanide/poly-ICLC/ipilimumab reshapes the T cell landscape in melanoma patients: - Strong CD8+ responses - TCR repertoires expanded beyond anti–PD-1 - Vaccine-specific TILs identified post-treatment www.cell.com/cell/abstrac...? #Neoantigen #Melanoma #Tcells
cell.comA multi-adjuvant personal neoantigen vaccine generates potent immunity in melanomaA personalized neoantigen peptide vaccine formulated with Montanide plus poly-ICLC
and administered with local ipilimumab plus systemic nivolumab induces robust neoepitope-specific
T cell responses an...
0 reposts0 likes